Filing Flows › Femasys (FEMY) › Recalls, complaints & regulation
Femasys (FEMY): clinical trials
Femasys (FEMY) beyond its filings: 2 active clinical trials.
Femasys' latest quarter
Femasys, Q2 2026: revenue $332K (-19% year over year), net loss $4.5M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Femasys have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.